Form 4: Foghorn Therapeutics Chief Medical Officer Acquires Stock Options

Foghorn Therapeutics' Chief Medical Officer, Alfonso Quintas Cardama, was granted stock options for 125,000 shares of common stock.

Summary

• Alfonso Quintas Cardama, the Chief Medical Officer of Foghorn Therapeutics, was granted stock options to purchase 125,000 shares of the company's common stock.
• The exercise price for these options is $4.37 per share.
• The options vest over time, with 25% vesting on January 22, 2026, and the remaining 75% vesting quarterly thereafter.
• The options expire on January 21, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and contribution from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Moderna, BioNTech, and Regeneron.
• The vesting schedule of 25% initially and then quarterly is a typical vesting structure for stock options.

Stakeholder Impact

• The stock option grant aligns the Chief Medical Officer's interests with those of shareholders, potentially leading to increased focus on company performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, Foghorn Therapeutics, FHTX, Alfonso Quintas Cardama, Chief Medical Officer